48,830
edits
m (→Sentinel lymph node biopsy: tweak wording) |
|||
Line 284: | Line 284: | ||
Notes: | Notes: | ||
*There is '''no''' mortality benefit from axillary lymph node dissection | *There is '''no''' mortality benefit from axillary lymph node dissection, i.e. positive axillary lymph nodes can be left in situ without affecting outcome.<ref>{{cite journal |author=Giuliano AE, Hunt KK, Ballman KV, ''et al.'' |title=Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial |journal=JAMA |volume=305 |issue=6 |pages=569–75 |year=2011 |month=February |pmid=21304082 |doi=10.1001/jama.2011.90 |url=}}</ref> | ||
**This does not negate the fact that a positive sentinel LN biopsy (vs. negative sentinel LN biopsy) portends a poorer prognosis. | |||
===Microscopic=== | ===Microscopic=== |
edits